This Article Full Text (PDF) All Versions of this Article: 1352458507079907v1 14/1/73    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sajja, B.R. Articles by N/A, t. P. T. M. G. Search for Related Content PubMed PubMed Citation Articles by Sajja, B.R. Articles by N/A, t. P. T. M. G. Social Bookmarking                   What's this?

Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study

Department of Diagnostic and Interventional Imaging, University of Texas Medical School at Houston, TX 77030, USA

P.A. Narayana

Department of Diagnostic and Interventional Imaging, University of Texas Medical School at Houston, TX 77030, USA, ponnada.a.narayana{at}uth.tmc.edu

J.S. Wolinsky

Department of Neurology University of Texas Medical School at Houston, TX 77030, USA

C.W. Ahn

Department of Internal Medicine, University of Texas Medical School at Houston, TX 77030, USA

the PROMiSe Trial MRSI Group N/A

N/A

Multicenter proton magnetic resonance spectroscopic imaging (MRSI) studies were performed on 58 primary progressive multiple sclerosis (PPMS) patients from four centers for investigating the efficacy of glatiramer acetate (GA) treatment. These patients were drawn from 943 subjects who participated in the PROMiSe trial. In these MRSI studies, patients were followed over a period of 3 years. MRSI data were acquired by all the centers using the same pulse sequence, and spectral analysis was performed at a single site using a customized analysis software package. Quantitative metabolite ratios, N-acetyl aspartate (NAA)/creatine (Cr) and choline (Cho)/Cr, were compared between GA-treated and placebo-treated PPMS patients. There was no significant difference in metabolite ratios between GA-treated and placebo-treated patients. The difference in metabolite ratios between the normal-appearing tissues (NAT) and lesion-containing regions (LCR) in GA treated patients was not significantly different from placebo treated patients. Strong lipid resonances, even in the absence of lesions, were observed on MRSI data in both gray matter and white matter in placebo- and GA-treated PPMS patients. No significant difference in number of patients with lipids between the two groups over a period of 3 years was found. Multiple Sclerosis 2008; 14: 73—80. http://msj.sagepub.com

Key Words: glatiramer acetate • MRI • MRSI • N-acetylaspartate • primary progressive multiple sclerosis • proton spectroscopic imaging

This version was published on January 1, 2008

Multiple Sclerosis, Vol. 14, No. 1, 73-80 (2008)
DOI: 10.1177/1352458507079907


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?